- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00076388
Iressa Versus Docetaxel (Taxotere)
12. maj 2011 opdateret af: AstraZeneca
A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding
1440
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Buenos Aires, Argentina
- Research Site
-
Cordoba, Argentina
- Research Site
-
El Palomar, Argentina
- Research Site
-
Mar del Plata, Argentina
- Research Site
-
Quilmes, Argentina
- Research Site
-
Rosario, Argentina
- Research Site
-
San Miguel de Tucuman, Argentina
- Research Site
-
Santa Fe, Argentina
- Research Site
-
-
-
-
-
Charleroi, Belgien
- Research Site
-
Edegem, Belgien
- Research Site
-
Genk, Belgien
- Research Site
-
Godinne, Belgien
- Research Site
-
Kortrijk, Belgien
- Research Site
-
Leuven, Belgien
- Research Site
-
Liège, Belgien
- Research Site
-
Yvoir, Belgien
- Research Site
-
-
-
-
RJ
-
Rio de Janeiro, RJ, Brasilien
- Research Site
-
-
RS
-
Porto Alegre, RS, Brasilien
- Research Site
-
-
SP
-
Sao Paulo, SP, Brasilien
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- Research Site
-
-
British Columbia
-
Surrey, British Columbia, Canada
- Research Site
-
-
New Brunswick
-
Moncton, New Brunswick, Canada
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada
- Research Site
-
London, Ontario, Canada
- Research Site
-
Newmarket, Ontario, Canada
- Research Site
-
St. Catherines, Ontario, Canada
- Research Site
-
Sudbury, Ontario, Canada
- Research Site
-
Toronto, Ontario, Canada
- Research Site
-
York, Ontario, Canada
- Research Site
-
-
Quebec
-
Laval, Quebec, Canada
- Research Site
-
Montreal, Quebec, Canada
- Research Site
-
Ste-Foy, Quebec, Canada
- Research Site
-
-
-
-
-
Aalborg, Danmark
- Research Site
-
Arhus C, Danmark
- Research Site
-
Glostrup, Danmark
- Research Site
-
Herlev, Danmark
- Research Site
-
København Ø, Danmark
- Research Site
-
Vejle, Danmark
- Research Site
-
-
-
-
-
Tallinn, Estland
- Research Site
-
Tartu, Estland
- Research Site
-
-
-
-
-
Manila, Filippinerne
- Research Site
-
Quezon City, Filippinerne
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater
- Research Site
-
-
California
-
Fountain Valley, California, Forenede Stater
- Research Site
-
Los Angeles, California, Forenede Stater, 90048
- Research Site
-
Santa Rosa, California, Forenede Stater
- Research Site
-
Stockton, California, Forenede Stater, 95204
- Research Site
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater
- Research Site
-
-
Connecticut
-
Norwich, Connecticut, Forenede Stater
- Research Site
-
-
Delaware
-
Newark, Delaware, Forenede Stater
- Research Site
-
-
Florida
-
Boca Raton, Florida, Forenede Stater
- Research Site
-
Orlando, Florida, Forenede Stater, 32806
- Research Site
-
-
Georgia
-
Macon, Georgia, Forenede Stater
- Research Site
-
Tucker, Georgia, Forenede Stater
- Research Site
-
-
Illinois
-
Skokie, Illinois, Forenede Stater, 60077
- Research Site
-
-
Kentucky
-
Knoxville, Kentucky, Forenede Stater
- Research Site
-
-
Minnesota
-
St. Louis Park, Minnesota, Forenede Stater
- Research Site
-
-
New York
-
Great Neck, New York, Forenede Stater, 11021
- Research Site
-
Rochester, New York, Forenede Stater, 14621
- Research Site
-
Syracuse, New York, Forenede Stater, 13210
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Research Site
-
Charlotte, North Carolina, Forenede Stater
- Research Site
-
Durham, North Carolina, Forenede Stater, 27710
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater
- Research Site
-
Pittsburgh, Pennsylvania, Forenede Stater
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater
- Research Site
-
-
Texas
-
Austin, Texas, Forenede Stater
- Research Site
-
Dallas, Texas, Forenede Stater
- Research Site
-
Houston, Texas, Forenede Stater, 77030-4009
- Research Site
-
Tyler, Texas, Forenede Stater
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater
- Research Site
-
-
Washington
-
Seattle, Washington, Forenede Stater
- Research Site
-
-
Wisconsin
-
Racine, Wisconsin, Forenede Stater
- Research Site
-
-
-
-
-
Blois, Frankrig
- Research Site
-
Boulogne Billancourt, Frankrig
- Research Site
-
Caen Cedex, Frankrig
- Research Site
-
Grenoble Cedex 09, Frankrig
- Research Site
-
Le Mans, Frankrig
- Research Site
-
Lille Cedex, Frankrig
- Research Site
-
Nantes, Frankrig
- Research Site
-
Niort, Frankrig
- Research Site
-
Saint Herblain, Frankrig
- Research Site
-
Vandoeuvre Les Nancy, Frankrig
- Research Site
-
Vesoul Cedex, Frankrig
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong
- Research Site
-
-
-
-
-
Jakarta, Indonesien
- Research Site
-
Yogyakarta, Indonesien
- Research Site
-
-
-
-
-
Napoli, Italien
- Research Site
-
Roma, Italien
- Research Site
-
-
Ancona
-
La Torretta, Ancona, Italien
- Research Site
-
-
BA
-
Bari, BA, Italien
- Research Site
-
-
BG
-
Bergamo, BG, Italien
- Research Site
-
-
BO
-
Bologna, BO, Italien
- Research Site
-
-
CN
-
Cuneo, CN, Italien
- Research Site
-
-
CT
-
Catania, CT, Italien
- Research Site
-
-
FO
-
Forli', FO, Italien
- Research Site
-
-
MI
-
Melegnano, MI, Italien
- Research Site
-
Rozzano, MI, Italien
- Research Site
-
-
MO
-
Modena, MO, Italien
- Research Site
-
-
PR
-
Parma, PR, Italien
- Research Site
-
-
TO
-
Torino, TO, Italien
- Research Site
-
-
-
-
-
Ankara, Kalkun
- Research Site
-
Istanbul, Kalkun
- Research Site
-
Izmir, Kalkun
- Research Site
-
-
-
-
-
Beijing, Kina
- Research Site
-
Guangzhou, Kina
- Research Site
-
Shanghai, Kina
- Research Site
-
-
-
-
-
Split, Kroatien
- Research Site
-
Zagreb, Kroatien
- Research Site
-
-
-
-
-
Riga, Letland
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia
- Research Site
-
Nilai, Malaysia
- Research Site
-
-
-
-
-
Guadalajara, Mexico
- Research Site
-
Monterrey, Mexico
- Research Site
-
Morelia, Mexico
- Research Site
-
Torreon, Mexico
- Research Site
-
-
-
-
-
Bellinzona, Schweiz
- Research Site
-
St. Gallen, Schweiz
- Research Site
-
Zürich, Schweiz
- Research Site
-
-
-
-
-
Singapore, Singapore
- Research Site
-
-
-
-
-
Ljubliana, Slovenien
- Research Site
-
-
-
-
-
Barcelona, Spanien
- Research Site
-
Gerona, Spanien
- Research Site
-
Madrid, Spanien
- Research Site
-
Málaga, Spanien
- Research Site
-
Sevilla, Spanien
- Research Site
-
Valencia, Spanien
- Research Site
-
Vitoria, Spanien
- Research Site
-
Zaragoza, Spanien
- Research Site
-
-
Alicante
-
Elche, Alicante, Spanien
- Research Site
-
-
-
-
-
Goteborg, Sverige
- Research Site
-
Luleå, Sverige
- Research Site
-
Skövde, Sverige
- Research Site
-
Stockholm, Sverige
- Research Site
-
Sundsvall, Sverige
- Research Site
-
Umeå, Sverige
- Research Site
-
Vasteras, Sverige
- Research Site
-
Örebro, Sverige
- Research Site
-
Östersund, Sverige
- Research Site
-
-
-
-
-
Chiang Mai, Thailand
- Research Site
-
-
-
-
-
Berlin, Tyskland
- Research Site
-
Bonn, Tyskland
- Research Site
-
Großhansdorf, Tyskland
- Research Site
-
Köln, Tyskland
- Research Site
-
Leverkusen, Tyskland
- Research Site
-
Löwenstein, Tyskland
- Research Site
-
Mannheim, Tyskland
- Research Site
-
München, Tyskland
- Research Site
-
Stuttgart, Tyskland
- Research Site
-
Wiesbaden, Tyskland
- Research Site
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Tyskland
- Research Site
-
Ulm, Baden-Württemberg, Tyskland
- Research Site
-
-
Brandenburg
-
Cottbus, Brandenburg, Tyskland
- Research Site
-
-
Hessen
-
Frankfurt, Hessen, Tyskland
- Research Site
-
-
Nordrhein-Westfalen
-
Düsseldorf, Nordrhein-Westfalen, Tyskland
- Research Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Tyskland
- Research Site
-
-
Schleswig-Holstein
-
Bad Segeberg, Schleswig-Holstein, Tyskland
- Research Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Measurable (uni dimensional) disease by RECIST criteria in a lesion not previously irradiated or non measurable disease
- Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy
- Advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy
- WHO performance status (PS) 0-2
- Absolute Neutrophil Count (ANC) >1.5 x 109/liter (L) and platelets >100 x 109/L
- Life expectancy of at least 8 weeks
Exclusion Criteria:
- Prior ZD1839 therapy
- Prior docetaxel treatment for NSCLC
- Less than 14 days since completion of prior radiotherapy
- Less than 21 days since prior chemotherapy, immunotherapy or biological systemic anticancer therapy
- Evidence of clinically active Interstitial Lung Disease
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days
- Patients with pre existing peripheral neuropathy >= grade 2 (NCI CTC criteria)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
|---|
|
To compare overall survival between ZD1839 and docetaxel
|
Sekundære resultatmål
Resultatmål |
|---|
|
To compare time to progression (TTP) between ZD1839 and docetaxel
|
|
To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel
|
|
To compare the overall objective tumor response rate between ZD1839 and docetaxel
|
|
To compare patient-reported functionality (PRF) and quality of life (QoL) between ZD1839 and docetaxel
|
|
To compare safety and tolerability of ZD1839 and docetaxel
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: AstraZeneca Iressa Medical Science Director, MD, AstraZeneca
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Lombard A, Mistry H, Aarons L, Ogungbenro K. Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2021 Apr;87(4):2053-2063. doi: 10.1111/bcp.14614. Epub 2020 Dec 19.
- Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.
- Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2004
Primær færdiggørelse (Faktiske)
1. marts 2007
Studieafslutning (Faktiske)
1. oktober 2007
Datoer for studieregistrering
Først indsendt
21. januar 2004
Først indsendt, der opfyldte QC-kriterier
22. januar 2004
Først opslået (Skøn)
23. januar 2004
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
13. maj 2011
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. maj 2011
Sidst verificeret
1. maj 2011
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Proteinkinasehæmmere
- Docetaxel
- Gefitinib
Andre undersøgelses-id-numre
- D791GC00001
- EudraCT No: 2004-002943-28
- 1839IL/0721
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ikke-småcellet lungekarcinom
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Universitaire Ziekenhuizen KU LeuvenAktiv, ikke rekrutterendeLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
Taichung Veterans General HospitalAfsluttetKardiotoksicitet | Non-Small Cell Lungecancer (MeSH Term: Carcinoma, Non-Small-Cell Lung) | Lægemiddelrelaterede bivirkninger og uønskede reaktioner (MeSH-betegnelse) | Egfr TyrosinkinasehæmmerTaiwan
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute of Cancer Research, United Kingdom og andre samarbejdspartnereRekrutteringIkke småcellet lungekræft | Metastatisk ikke-småcellet lungekræft | Locally Advanced NSCLC - Ikke-småcellet lungekræft | Oncogen-afhængig ikke-ikke-cellelungecancer | Tidlig fase Operable Non Small Cell Lung Cancer | Trin 2/3 Operable Non Small Cell Lung CancerDet Forenede Kongerige
-
Fondazione del Piemonte per l'OncologiaRekrutteringBrystkræft | Livmoderhalskræft | Colo-rektal cancer | Melanom (hudkræft) | Non-Small Cell Lungecancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)Italien
-
Zelluna Immunotherapy ASRekrutteringHoved- og halskræft | Livmoderhalskræft | Synoviale sarkomer | Squamous Non-Small Cell Lung Cancer (NSCLC)Det Forenede Kongerige
-
National Cancer Institute (NCI)AfsluttetIldfast malignt fast neoplasma | Tilbagevendende malignt fast neoplasma | Metastatisk malignt fast neoplasma | Uoprettelig fast neoplasma | Tilbagevendende småcellet lungekarcinom | Stadie IIIA Lunge småcellet karcinom AJCC v7 | Stadie IIIB Lunge småcellet karcinom AJCC v7 | Stadie IV lunge småcellet... og andre forholdForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeSezary syndrom | Refraktær T-celle non-Hodgkin lymfom | Merkel cellekarcinom | Anaplastisk storcellet lymfom, ALK-positivt | Ekstramammær Paget sygdom | Tilbagevendende T-celle non-Hodgkin lymfom | Tilbagevendende moden T-celle og NK-celle non-Hodgkin lymfom | Refraktær moden T-celle og NK-celle non-Hodgkin... og andre forholdForenede Stater
-
ITM Oncologics GmbHRekrutteringTredobbelt negativ brystkræft (TNBC) | Pancreas Ductal Adenocarcinom (PDAC) | Kolorektal cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC) | Urotelcarcinom (UC) | Ubestemt nyremasse (IDRM) | Muskelinvasiv blærekræft (MIBC) | Hoved- og halskræft (H&N) | Squamous Non-Small Cell Lung Cancer (NSCLC)Frankrig, Australien
Kliniske forsøg med Docetaxel
-
Nereus Pharmaceuticals, Inc.AfsluttetKræftForenede Stater, Australien, Indien, Chile, Brasilien, Argentina
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical... og andre samarbejdspartnereUkendt
-
Instituto do Cancer do Estado de São PauloIkke rekrutterer endnuProstatakræft (Adenocarcinom)Brasilien
-
AkesoRekrutteringIkke-småcellet lungekræftKina
-
Zhuhai Beihai Biotech Co., LtdAfsluttetFaste tumorer | Bioækvivalens | DocetaxelIndien
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAfsluttetIkke-småcellet lungekræft (NSCLC)Kina
-
Arog Pharmaceuticals, Inc.Trukket tilbageKarcinom, ikke-småcellet lunge
-
Guangdong Provincial People's HospitalShanghai Henlius BiotechAktiv, ikke rekrutterende
-
Optimal Health ResearchAfsluttetBrystkræft | Lungekræft | ProstatakræftForenede Stater